MTOR and endometrial cancer: Endometrial cancer organoids were amenable to drug screening of standard chemotherapies, demonstrating patient-specific drug responses, in particular sensitivity to mTOR inhibition in line with mutations in the PI3K/AKT/mTOR signalling pathway [29].